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SUMMARY 
The effects of agonists and partial agonists of both mu and kappa recep- 
tor systems are described in several behavioral tests in rhesus monkeys. 
Procedures measuring drug discrimination, drug self-administration, drug 
dependence, and drug-induced analgesia are differentially sensitive to the 
agonist and antagonist effects of various opioids. The sensitivity of each of 
the procedures may be modified by altering behavioral parameters or dose of 
drug used to establish the behavioral effect. 
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INTRODUCTION 
‘The term agonist-antagonist as applied to opioid analgesics and their 
central nervous system actions has thus come to involve two concepts: 
1) the concept of multiple receptors; 2) the concept of partial agonists’ [ 11. 
This description of the basic attributes of opioid agonist-antagonists, also 
referred to as partial agonists or mixed agonist-antagonists, hints at the 
complex nature of these drugs and the difficulties involved in classifying 
them and interpreting their actions. It must be determined through which of 
the multiple opioid receptors any given drug exerts agonist effects. In addi- 
tion, the nature of its partial agonist properties, on this same or another 
receptor, must be described. The emphasis of the present paper is on the 
various procedures that have yielded information about agonist and partial 
agonist actions of opioids in the rhesus monkey. It seems clear that proce- 
dures that do an excellent job of indicating the receptor system on which a 
drug acts in the monkey do not necessarily yield concomitant information 
about the nature of the partial agonist effects of opioids. 
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Martin [2] proposed different types of opiate receptors based on differen- 
tial, naloxone-sensitive actions of specific opioids in several preparations. 
Since that time, and with elaborations by Martin et al. [3] in the spinal dog, 
the distinct opiate actions mediated by two of these receptors, the mu recep- 
tor with morphine as the prototype and the kappa receptor with ketocycla- 
zocine as the prototype, have been well documented in a number of 
behavioral systems. 
The rhesus monkey has been an especially useful species to differentiate 
mu and kappa opiates. The measures of opioid actions in this species have 
included analgesia, discriminative stimulus effects, fluid balance, reinforc- 
ing effects, tolerance and dependence. Each of these measures, with the 
exception of analgesia, in which both mu and kappa agonists are active, 
demonstrate the distinctive effects of mu and kappa opioids in the monkey. 
Even with analgesia, pA2 studies in the monkey indicate this effect may be 
mediated through two different receptors, mu and kappa [4]. 
PROCEDURES 
Drug discrimination 
Tests of discriminative stimulus effects have been particularly useful 
in differentiating mu and kappa opioids in the rhesus monkey. In this 
type of preparation, monkeys are trained to respond differentially (i.e. 
on one of two levers) depending on whether they have received an injec- 
tion of a particular drug or an injection of vehicle. Monkeys trained to 
indicate administration of a mu agonist such as codeine will respond on 
the codeine-appropriate lever following administration of active doses of 
other mu agonists. Likewise, monkeys trained to respond on one of two 
levers following administration of a kappa agonist such as EKC, will re- 
spond on this lever following administration of other kappa agonists. 
Figure la shows the effects of alfentanil and EKC in three rhesus monkeys 
trained to discriminate the effects of 1.0 mg/kg codeine. Alfentanil 
produced codeine-like discriminative stimulus effects in these monkeys, 
whereas EKC did not. In contrast, as shown in Fig. lb, the kappa agonist 
U-50488 had discriminative stimulus effects in common with EKC in 
three monkeys trained to indicate the interoceptive effects of 0.0032 mg/kg 
EKC, whereas alfentanil did not. The generality of this finding is 
indicated by the fact that mu agonists such as morphine, etorphine, 
I-alphaacetylmethadol (LAAM), and methadone have each been shown 
to produce codeine-, but not EKC-like discriminative stimulus effects in 
the monkey [5] whereas kappa agonists such as ketazocine, tifluadom, 
bremazocine, and MR2033, (+)-(1 R/S, 5 R/S, 2” R/S)-5,9-dimethyl-2’- 
hydroxy-2-tetrahydrofurfuryl-6,7-benzomorphan HCl) produced EKC-like but 
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Pig. 1. Discriminative stimulus effects of alfentanil and EKC in monkeys trained to discrimi- 
nate 1.0 mg/kg codeine from saline (a) and of alfentanil and U-50488 in monkeys trained to dis- 
criminate 0.0032 mg/kg EKC (b). Abscissae: dose of test drugs in mg/kg. Ordinates: percent of 
the total responses made on the codeine- (a) or EKC- (b) appropriate levers. 
A number of mixed agonist-antagonists have been evaluated in rhesus 
monkeys trained to discriminate either the mu agonist etorphine 
(0.00032 mg/kg) or the kappa agonist EKC (0.0032 mg/kg). Nalorphine and 
I-cyclazocine produced 100% EKC-appropriate responding in all tested mon- 
keys [ 51. The agonist-antagonists buprenorphine, butorphanol, d-profadol, 
propiram, and nalbuphine did not produce discriminative effects in common 
with EKC; all produced more than 90% responding on the etorphine- 
appropriate lever indicating mu-like discriminative effects [ 71. 
Drug self-administration 
The difference in reinforcing effects of mu and kappa opioids is indicated 
in Fig. 2 by comparing a mu agonist, alfentanil, with a kappa agonist, 
U-50488, on measures of rate of responding maintained by intravenous pre- 
sentation of these drugs to rhesus monkeys. Under the conditions of these 
experiments, monkeys were given access to 0.32 mg/kg per injection codeine 
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Fig. 2. Reinforcing effects of alfentanil (a) and U-50488 (b) in monkeys experienced with self- 
administration of 0.32 mg/kg per inj. codeine. The open circles indicate the average rate of 
codeine (COD)- or saline (SAL)- reinforced responding in a group of 20 monkeys. The two top- 
most dashed lines are +3 S.E.M. of this codeine average, and the bottommost dashed line is 
+3 S.E.M. of this saline average. Closed circles represent average codeine, saline and alfen- 
tanil- or U-50588.reinforced responding in three monkeys tested with these drugs. Each monkey 
was tested twice at each indicated dose. Abscissae: dose of alfentanil (a) or U-50488 (b), in mg/ 
kg per inj., used to evaluate the reinforcing effects of these drugs. Ordinates: responses per 
second. 
during two daily 130-min sessions. This dose of codeine was delivered conse- 
quent to 30 responses by the monkey on an available lever, and each drug 
delivery was followed by a signalled IO-min time-out period when respond- 
ing had no consequence. When rates of codeine-maintained responding were 
stable and above 1 response/s, substitutions of the indicated doses of alfen- 
tanil, U-50488, or saline were made every third session. Each monkey re- 
ceived each dose on two occasions. The data points shown indicate the 
mean rates of responding in at least three monkeys. Rates of responding 
maintained by alfentanil reached more than 2 responses/s at the maximal 
rate-maintaining dose of 0.01 mg/kg per inj. Rates of responding maintained 
by U-50488, however, were never higher and were frequently lower 
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than rates maintained by saline. These differential reinforcing effects of mu 
and kappa agonists have been demonstrated with a wide variety of com- 
pounds, including the mu agonists, morphine, codeine, methadone, and 
heroin, and the kappa agonists, EKC, ketocyclazocine, and bremazocine. A 
few exceptions exist, related to the onset and duration of action of the drugs 
in question. LAAM, for example, is a long-acting, mu opioid that does not 
maintain drug self-administration in rhesus monkeys (Bertalmio, unpub- 
lished observations). 
That the reinforcing effects are mediated by opioid receptors is suggested 
by the fact that a surmountable antagonism of the reinforcing effects of 
alfentanil may be obtained with the opioid antagonist quadazocine. The pA2 
for quadazocine as an antagonist of the reinforcing effects of alfentanil 
closely approximates the pA2 obtained with the discriminative stimulus 
effect of this drug and other mu agonists [8]. 
A number of mixed agonist-antagonists have been tested for their rein- 
forcing effects in the procedure described above. The reinforcing effects of 
buprenorphine, butorphanol, nalbuphine, pentazocine and picenadol have 
been investigated in the rhesus monkey. Each of these drugs has been 
shown to maintain intravenous self-administration, but at rates below those 
maintained by codeine [7]. Thus, with this behavioral effect, these com- 
pounds appear to share actions with mu rather than kappa opioids. The fact 
that they are not as efficacious as codeine suggests that they may be partial 
agonists in this system. However, further evaluation of the reinforcing 
effects must be undertaken to determine whether effects less than those pro- 
duced by codeine indicate partial agonist effects or can be explained by 
some other mechanisms. Morphine, which is a full agonist in most other sys- 
tems, does not maintain rates of responding as high as those maintained by 
codeine, which raises the possibility that there may be inherent differences 
among these drugs that serve to modulate the expression of their reinforc- 
ing effects in this paradigm. It will be necessary to modify the procedures so 
that drugs known to have full agonist. effects produce similar, high rates of 
reinforced responding. It may be then possible to determine more precisely 
whether the mixed agonist-antagonists tested yield data indicating full or 
partial agonist effects. 
Neither nalorphine, oxilorphan nor levallorphan maintained intravenous 
self-administration in the monkey [7], and there are some data from our lab- 
oratory and others [9] that nalorphine may have aversive effects. Likewise, 
I-cyclazocine did not maintain drug self-administration, although d-cycla- 
zocine, with considerable phencyclidine-like activity in the monkey, showed 
a very modest amount of reinforcing activity [lo]. 
Urination 
The capacity of kappa, but not mu opioids, to produce increases in urine 
output has been demonstrated in rodents [ll]. A similar finding has been 
reported in rhesus monkeys with bremazocine, EKC, MR 2033, tifluadom 
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and U-50488 [4]. Few mixed agonist-antagonists have been evaluated in tests 
of urine output in the rhesus monkey, so the capacity of this test to indicate 
partial agonist actions has not yet been determined. 
Physiological dependence 
Morphine-dependent monkeys deprived of morphine demonstrate charac- 
teristic withdrawal signs that are quite different from those shown by mon- 
keys made dependent on the selective kappa agonist U-50488 and deprived 
of this opiate. Table I lists the various withdrawal signs associated with ter- 
mination of chronic morphine or chronic U-50488 administration. Signs of 
morphine withdrawal are not attenuated by administration of kappa opiates 
such as EKC or U-50488, but are blocked by administration of mu agonists 
such as methadone, LAAM or diacetylmorphine. Kappa opiates, such as 
EKC and tifluadom, but not mu opiates, will attenuate the signs of U-50488 
withdrawal [ 121. 
The nature of the agonist and antagonist actions of drugs with both mu 
and kappa effects can be characterized to some extent in monkeys made de- 
pendent on either morphine or U-50488. Furthermore, the withdrawal signs 
that develop following chronic administration of agonist-antagonists can 
also provide evidence as to the nature of their opioid activity. In addition, 
the administration of relatively pure opioid antagonists to monkeys receiv- 
ing an agonist-antagonist chronically may serve to support (and, perhaps, 
complicate) the information obtained following drug discontinuation. 
The antagonist effects of buprenorphine were evidenced by its capacity 
to produce withdrawal signs in both morphine-dependent and U-50488- 
dependent monkeys [12]. It appeared to have little capacity to produce 
dependence on its own, however, since no withdrawal signs were observed 
following either abrupt discontinuation or naloxone administration in mon- 
keys receiving buprenorphine chronically. Work by Dum et al. [13] sug- 
gested that dependence to buprenorphine does develop, but it is not easy to 
TABLE I 
DEPRIVATION-INDUCED WITHDRAWAL SIGNS 
Morphine-Dependent Monkeys 
Apprehension and aggression during handling 
Abdominal twitching during handling 
Abdominal defense reaction to palpation (cramping) 
U-5048SDependent Monkeys 
General hyperactivity in cage 
Excessive scratching 
Excessive grooming of other monkeys 
Yawning 
Unusual tongue movements 
Picking at fingers and toes 
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observe because the drug is difficult to displace from its receptor. Thus, 
special procedures are necessary to reveal buprenorphine’s dependence 
capacity. 
Studies of dependence to this and other mixed agonist-antagonists have 
been recently reviewed by Woods and Gmerek [14]. As they note, nal- 
buphine was also able to produce withdrawal signs when administered to 
morphine-dependent monkeys; chronic administration of nalbuphine re- 
sulted in mu-like withdrawal signs both on abrupt drug discontinuation and 
on administration of naloxone. Butorphanol neither suppressed nor exacer- 
bated morphine withdrawal in morphine-dependent monkeys. Naloxone elic- 
ited severe morphine-like withdrawal signs in monkeys receiving 
butorphanol chronically, but when butorphanol was withdrawn abruptly, 
the withdrawal signs were more like U-50488 withdrawal than like morphine 
withdrawal. This somewhat anomalous profile of action may be due to the 
greater affinity of naloxone for the mu than the kappa receptor. A similar 
picture of naloxone-precipitated mu-withdrawal signs, and deprivation-in- 
duced kappa-withdrawal signs was produced by picenadol, although the 
naloxone-precipitated withdrawal signs were less severe during picenadol 
administration than were those produced during chronic butorphanol ad- 
ministration. Pentazocine, like butorphanol, did not alter the withdrawal 
signs in morphine-dependent monkeys. Pentazocine withdrawal signs, fol- 
lowing pentazocine discontinuation or naloxone administration, were pri- 
marily kappa-like. 
Kappa-like withdrawal signs were observed following discontinuation of 
chronic administration of cyclazocine and nalorphine [ 151. Nalorphine pre- 
cipitated withdrawal in monkeys dependent on U-50488, although the dose 
required to precipitate U-50488 withdrawal was much higher than that nec- 
essary to precipitate morphine withdrawal [ 121. Bremazocine precipitated 
withdrawal in morphine-dependent monkeys, but suppressed withdrawal in 
U-50488-dependent monkeys [ 121. 
Sedation 
Although the effects of mu and kappa opioid agonists are clearly distinc- 
tive in tests of discriminative and reinforcing effects, and with measures of 
physiological dependence, with measures of analgesia and sedation there is 
overlap between the effects of mu and kappa opiates in the rhesus monkey. 
Even with these latter effects, however, distinctions can be made. As demon- 
strated in Fig. 3, the marked tolerance that develops to the sedative effects 
of U-50488 during chronic administration of this drug is not accompanied by 
cross tolerance to similar sedative actions of morphine [16]. There has, as 
yet, been little further evaluation of cross tolerance to mu and kappa ago- 
nists in the monkey. Measures of cross tolerance between U-50488 and other 
opioid agonists or agonist-antagonists should, however, help identify their 
action on kappa receptors. Likewise, measures of cross tolerance between 
morphine and other opioids would be expected to develop only to the extent 
that the other compound shares mu agonist activity. 
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Fig. 3. The effect of U-50488 and morphine on muscle relaxation in monkeys receiving chronic 
injections of U-50488. U-50488 was given just prior to the first day of chronic administration 
(open circles; n = 6) and on day 92 of chronic administration (closed circles; n = 3). Morphine 
was given 1 week prior to the chronic administration of U-50488 (open squares; n = 6) and on 
day 92 of chronic U-50488 administration (closed squares; n = 3). From [ 161. 
Analgesia 
In addition to measures of reinforcing effects, discriminative stimulus 
effects, dependence producing potential, and capacity to produce or attenu- 
ate morphine withdrawal, agonist-antagonists have also been evaluated for 
their capacity to produce analgesia in the rhesus monkey. Tests for analge- 
sia are extremely important, since analgesia is the clinical response for 
which these drugs are being evaluated. Analgesia in the rhesus monkey was 
indicated by measuring the time required for the monkey to pull its tail 
from a thermos of 50” or 55” water [17]. A cut-off time of 20 s set the maxi- 
mum amount of analgesia. The water temperature has been shown to affect 
the amount of analgesia a given compound will produce; mu agonists were 
slightly more effective analgesics in 55” as compared to 50” water, whereas 
some kappa agonists were more effective analgesics when the water temper- 
ature was 50” [HI. 
As shown in Table II, using 55” water, the mu agonist morphine and the 
kappa agonists ethylketocyclazocine U-50488 and bremazocine each pro- 
duced 100% analgesia in this assay. 
Butorphanol and nalbuphine, included as mu agonists by virtue of their 
codeine-like discriminative effects, showed a partial agonism, as indicated 
by a less than 100% analgesic response. 
Drugs that produce EKC-like discriminative effects are grouped as kappa 
drugs in Table II, and are segregated by their capacity to produce analgesia. 
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TABLE II 
COMPARISON OF ANALGESIC EFFICACY AND POTENCY TO DISCRIMINATIVE 
POTENCY IN RHESUS MONKEYS 
% of Largest 
maximum dose 
possible tested 
effect (n = 10) (mg/kg) 
Dose necessary to produce 
discriminative effects 
equivalent to 
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As with the drugs acting on mu receptors, kappa drugs can be categorized 
as full or partial agonists or antagonists based on their capacity to produce 
analgesia in the tail-withdrawal assay. Cyclazocine and levallorphan each 
produced analgesia that was considerably less than that produced by EKC, 
U-50488, or bremazocine; oxilorphan and nalorphine produced no analgesia, 
even at very high doses. Kappa drugs with less analgesic effects should be 
able to produce partial (cyclazocine and levallorphan) or full (oxilorphan 
and nalorphine) antagonism of the analgesia produced by EKC, U-50488, 
and bremazocine. Likewise, butorphanol and nalbuphine should be able to 
antagonize, to some extent, the analgesia produced by morphine. These pre- 
dictions are currently being explored in our laboratory. 
DISCUSSION 
It is clear from the above information that some of the different proce- 
dures used for evaluating opioids in the rhesus monkey do not demonstrate 
partial agonist properties of opioids that have both agonist and antagonist 
actions in other systems. It has been known for some time that the nature 
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of the preparation studied is important in indicating the various aspects of 
mu opioid action. The guinea pig ileum, for example, is more sensitive to 
the agonist actions of opioids than is the mouse vas deferens [19]. More 
thorough evaluation of the effects of opioids in different smooth muscle 
preparations indicated that the guinea pig ileum, mouse vas deferens, rat 
vas deferens, and rabbit vas deferens were quite different in their indication 
of the potency of mu and kappa agonist actions [20]. 
Similar differences in sensitivity to agonist and antagonist actions is 
clearly evident in behavioral preparations in the rhesus monkey. The effects 
of opioid agonists, antagonists and mixed agonist-antagonists have a profile 
of activity across different behavioral procedures in the monkey that ap- 
pears to reflect, fairly directly, action at opioid receptors. There is clearly a 
need to explore more thoroughly the behavioral effects of mixed agonist-an- 
tagonists in order to explain, categorize and classify the actions of these 
drugs. It is possible that further descriptions of the actions of mixed ago- 
nist-antagonists will be possible by modifying the various behavioral proce- 
dures in use. Although drug discrimination procedures, as described in the 
rhesus monkey, do not demonstrate partial agonist effects of opioids, studies 
by Holtzman [Sl] and Colpaert [ 221 in the rat and by Koek (unpublished 
observations) in the pigeon indicate that partial agonist effects of opioids 
may be demonstrated quite clearly using drug discrimination procedures. 
One critical variable appears to be the dose of drug used as the training 
stimulus: if a relatively low dose is used to train the discrimination, drugs 
that have been shown to have partial agonist effects in other systems are 
more likely to appear as full or partial agonists in the drug discrimination 
paradigm. If a higher dose is used to train and maintain the discrimination, 
these same drugs are more likely to appear as antagonists. This capacity of 
lower training doses to reveal a partial agonist effect of various opioids may 
hold as well in drug discrimination procedures as used in the rhesus mon- 
key, but this has not been carefully evaluated as yet. 
The ability to change the sensitivity of a given preparation to the effects 
of opioids may have a parallel in studies with in vitro preparations. Smith 
[23] demonstrated that increasing the intensity of the electrical stimulus 
to the mouse vas deferens abolished the agonist effects of morphine, but 
not those of an opioid peptide that had full agonist effects. Thus, para- 
metric changes in various preparations, both behavioral and in vitro, may 
assist in pointing out relative agonist and antagonist actions of various 
opioids. 
In studies of opioids as reinforcers, it is also quite possible that changes 
in the schedule of reinforcement or its parameters could alter the threshold 
with respect to partial agonist effects of drugs. It is known that changes in 
the time-out following each delivery of drug will result in changes in the 
potency of the reinforcing effects of drugs (compare Ref. 24 to Ref. 25). Us- 
ing different fixed-ratio values or using fixed-interval schedules of reinforce- 
ment could also shift the dose-effect curve [26]. It may thus be possible to 
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select parameters in these procedures that would demonstrate partial ago- 
nist effects. 
The current procedure of evaluating the capacity of opioids to precipi- 
tate, reverse or exacerbate withdrawal in morphine-dependent monkeys is 
capable of demonstrating the antagonist effects of mixed agonist-antago- 
nists. Drugs such as nalorphine, bremazocine, nalbuphine, and buprenor- 
phine, which are full agonists of either the mu or kappa type in tests of 
discriminative effects, show mu antagonist effects in morphine-dependent 
monkeys. Even here, however, the parameters of dependence may determine 
the potency of antagonist action of the mixed agonist-antagonists. In hu- 
mans made dependent on morphine, the dose used to establish morphine- 
dependence determined to some extent the drugs that produced 
morphine withdrawal [27]. Thus, altering the dose of mu or kappa agonist 
used to maintain dependence, and perhaps necessarily, developing more sen- 
sitive measures of withdrawal reactions, may assist in the behavioral char- 
acterization of mixed agonist-antagonists. 
Measures of analgesia in the rhesus monkey provide some of the most 
interesting data about the mixed agonist-antagonist opioids. Here, partial 
agonist effects can be demonstrated in the pharmacologically appropriate 
way, by producing less than the maximum effect. Used in conjunction with 
tests of discriminative stimulus effects, where the nature of the receptor on 
which the drug acts can be easily determined, tests of analgesia apparently 
allow drugs to be ordered on the basis of their relative efficacy. 
Interestingly, the analgesia measure of opioid effect in the monkey re- 
quires relatively higher doses of drug to produce a criterion response than 
does the measure of drug discrimination. As is shown in Table II, the dose 
of morphine required to produce a full agonist effect as an analgesic was 10 
times higher than that required to produce a full agonist effect as a discrim- 
inative stimulus. The partial agonist, nalbuphine, produced full agonist 
effects in the drug discrimination procedure at a dose of 0.01 mg/kg, but was 
unable to produce a full agonist effect as an analgesic at a dose of 32 mg/kg. 
It is clear from these data that, under the experimental conditions used (i.e. 
with the specified training dose for drug discrimination and the specified 
temperature for analgesia), fewer receptors must be activated to produce the 
discriminative effect than must be activated to produce analgesia. As de- 
scribed by Miller et al. [20] for in vitro preparations, the amount of receptor 
reserve may differ considerably between these two procedures. What re- 
mains to be determined is the extent to which the potency of drugs will 
change as the parameters used to establish and maintain the behaviors in- 
volved are modified. 
The data presented in this paper demonstrate that behavioral measures 
in the rhesus monkey vary in their capacity to indicate agonist, antagonist 
and partial agonist actions on the mu and kappa opioid receptor systems. 
When used in conjunction, these procedures allow a fairly complete picture 
to be drawn of the actions of individual drugs. It is possible that each of the 
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test systems can be modified in systematic ways so that more thorough de- 
scriptions can be made within a single procedure. It is clear, however, that 
different behavioral effects are profoundly modulated by the behavioral and 
pharmacological variables utilized. 
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DISCUSSION 
Dr. Lasagna: You showed a shift of the curve to the left of the kappa agonist after a mu 
antagonist. Is that a general phenomenon with other kappa-agonists and what’s the explana- 
tion? 
Dr. Woods: We’ve only tried beta-FNA with ethylketazocine, so I don’t know how general it 
is. It really needs to be repeated a number of times with other agonists. 
Dr. Yanagita: In your second slide and the last slide, you showed butorphanol as a mu ago- 
nist. But there are data showing a tremendous species differences between animals and hu- 
mans. Even among animals, there are species differences. In animals, it is a mu agonist, but it 
also has antagonistic properties in rats. In the monkey, however, this antagonistic activity is 
very low. In addition, in humans, it doesn’t look like a mu-type of drug. 
Dr. Woods: I concur entirely with your point. I don’t think that we should make gross gen- 
eralizations about the nature of compounds until we have looked at a wide variety of species, 
measures, etc. I call butorphanol a mu, perhaps partial, agonist, because it has limited anal- 
gesic activity in this particular test, and it appears to be mu-like in its discriminative and rein- 
forcing effects in monkeys. And I would think on the basis of those effects that at least there is 
an indication of it having some mu activity in the monkey. 
Dr. Harris: I would like to make a comment and a question. First of all, I apologize if I ever 
gave the impression that the kappa drugs do not produce physical dependence. I meant depen- 
dence of the morphine-type. The question is that I’m confused by nalmefine being classified by 
you on the basis of its discriminative stimulus effects as a kappa agonist when we find nothing 
in the pharmacology of that compound which resembles so-called kappa activity at all. It’s a 
mu agonist and antagonist, but we could see little behavioral activity. How do you explain its 
kappa actions in the discriminative stimuli paradigm? 
Dr. Woods: The doses that are used in a drug discrimination assay with ethylketazocine are 
extremely small, so just a very marginal intrinsic activity may be sufficient to produce the dis- 
criminative stimulus effect. We intend to test that hypothesis by using different training doses 
and we should be able to make a differentiation. I’m nervous about that particular effect, as 
well, because I, too, am not aware of nalmefine having any kappa activity with an exception of 
this one behavioral assay. 
Dr. Cook: Did you show, among the pure kappa agonists, greater intrinsic activity in pro- 
ducing analgesia in the monkey than with mixed agonist-antagonists? 
Dr. Woods: That’s right. 
Dr. Cook: And was the difference that bremazocine produces lOO%, which I assume is the 
cut-off, whereas a mixed-agonist produces only lo%? 
Dr. Woods: It depends upon which mixed agonist you are talking about. 
Dr. Cook: I think it was nalbuphine. 
Dr. Woods: Nalbuphine is in a mu-category for us, because it has mu-agonist actions in the 
monkey. 
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Dr. Cook: So it produced what level of analgesia? 
Dr. Woods: If I remember correctly, it was 10%. 
Dr. Cook: O.K. But whether the kappa agonist is associated with mu or whether it’s not, 
you see clear differences? 
Dr. Woods: Yes. Their partial agonist actions do not depend upon what kind of receptor 
they are working at. 
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